REPORT FROM THE 26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – Patients with clinically isolated syndrome (CIS) suggestive of MS treated with an immunomodulatory therapy are at high risk of stopping treatment once they experience a relapse, according to an analysis of data from the MSBase Incident Study (MSBASIS) (Spelman et al. ECTRIMS 2010; abstract P819).